NEW YORK (360Dx) – Proteomics firm Provista Diagnostics has completed a study indicating that its Videssa Breast test could eliminate as many as 45 percent of unnecessary breast biopsies.

The Scottsdale, Arizona-based company is now looking for a partner to lead commercialization of the test and for additional funding to drive the commercialization effort, said Gary Altman, Provista's CEO.

Altman was appointed CEO in February 2018, taking over for David Reese, who headed the firm from 2011 to 2017. Altman was previously chief operating officer at Human Longevity.